"Rank","Title","Status","Study Results","Conditions","Interventions","Locations","URL"
1,"Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease","Not yet recruiting","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: Empagliflozin|Drug: Placebo","University of Coloardo Anschutz Medical Campus, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT05510115"
2,"Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease","Active, not recruiting","No Results Available","Polycystic Kidney, Autosomal Dominant","Behavioral: Dietary","University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT04534985"
3,"Bosutinib For Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Bosutinib|Drug: Placebo","Southwest Kidney Institute, PLC, Phoenix, Arizona, United States|Southwest Clinical Research Institute, LLC, Tempe, Arizona, United States|Southwest Kidney Institute, PLC, Tempe, Arizona, United States|Capital Nephrology Clinical Research, Sacramento, California, United States|Boise Kidney & Hypertension Institute, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension Institute, PLLC, Meridian, Idaho, United States|Renal Associates of Baton Rouge, Baton Rouge, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Washington University, St. Louis, Missouri, United States|New York University - HHC CTSI Clinical Research Center, New York, New York, United States|Doylestown Hospital MRI, Doylestown, Pennsylvania, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|Nephrology/Hypertension Specialists, Doylestown, Pennsylvania, United States|Renal Associates, PA, San Antonio, Texas, United States|San Antonio Kidney Disease Center Physicians Group, P.L.L.C., San Antonio, Texas, United States|University of Virginia Health System - Nephrology, Charlottesville, Virginia, United States|University of Virginia Health System, Charlottesville, Virginia, United States|The Polyclinic, Seattle, Washington, United States|Renal Remission and Hypertension Clinic, Silverdale, Washington, United States|Monash Medical Centre, Clayton, Victoria, Australia|Toronto General Hospital, Toronto, Ontario, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|Klinika gerontologicka a metabolicka, Hradec Kralove, Czech Republic|Krajska nemocnice Liberec, Liberec 1, Czech Republic|Nemocnice Nove Mesto na Morave, Nove Mesto na Morave, Czech Republic|Fakultni poliklinika VFN, Praha 2, Czech Republic|Vseobecna fakultni nemocnice v Praze, Praha 2, Czech Republic|Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czech Republic|PRA Magyarorszag Kft. Klinikai Farmakologiai Vizsgalohely, Budapest, Hungary|Fovarosi Onkormanyzat Szent Imre Korhaz BSZMI Klinikai Farmakologiai Reszlege, Budapest, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont I.sz.Belgyogyaszati Klinika, Szeged, Hungary|Istituti Ospitalieri di Cremona, Cremona, Italy|A.O. Universitaria Ospedali Riuniti di Foggia, Foggia, Italy|Seoul National University Hospital, Department of Internal Medicine, Seoul, Korea, Republic of|Samsung Medical Center/Division of Nephrology, Seoul, Korea, Republic of|Eulji General Hospital, Seoul, Korea, Republic of|Vilnius University Hospital Santariskiu Clinic, Public Institution, Centre of Nephrology, Vilnius, Lithuania|Spitalul Clinic Republican, Chisinau, Moldova, Republic of|Zaklad Diagnostyki Chorob Serca, II Katedra Kardiologii, Gdansk, Poland|Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych, Gdansk, Poland|Specjalistyczny Szpital Zachodni im. Jana Pawla II w Grodzisku Mazowieckim, Grodzisk Mazowiecki, Poland|Krakowskie Centrum Medyczne NZOZ, Krakow, Poland|Klinika Nefrologii, Hipertensjologii i Chorob Wewnetrznych Katedry Chorob Wewnetrznych UWM, Olsztyn, Poland|Pracownia Echokardiografii, Oddzial Kardiologii, Olsztyn, Poland|Centrum Medyczne Aesculap, Radom, Poland|Klinika Kardiologii, Szczecin, Poland|Klinika Nefrologii, Transplantologii i Chorob Wewnetrznych, Szczecin, Poland|Szpital Powiatowy w Wolominie, Wolomin, Poland|SPZOZ Akademicki Szpital Kliniczny im. J. Mikulicza - Radeckiego, Wroclaw, Poland|Spitalul Clinic Municipal Dr. Gavril Curteanu Oradea, Oradea, jud. Bihor, Romania|Spitalul Clinic Dr. C. I. Parhon Iasi, Iasi, jud. Iasi, Romania|Institutul Clinic Fundeni, Centrul de Medicina Interna-Nefrologie, Bucuresti, Romania|SPITALUL CLINIC JUDETEAN DE URGENTA TIMISOARA ,Clinica de Nefrologie, Timisoara, Romania|Univerzitna nemocnica Bratislava, Limbova 5, Bratislava, Slovakia|SUMMIT CLINICAL RESEARCH, s.r.o., Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia|Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Sahlgrenska Universitetssjukhuset, Njurmedicin, Goteborg, Sweden|Karolinska Universitetssjukhuset Huddinge, Stockholm, Sweden|Karolinska Universitetssjukhuset Solna, Stockholm, Sweden|Universitaetsspital Zuerich, Zuerich, Switzerland|Istanbul University, Istanbul Tip Fakultesi, Istanbul, Capa, Turkey|Dokuz Eylul Universitesi Hastanesi Ic Hastaliklari Anabilim Dali, Izmir, Inciralti/ Narlidere, Turkey|Morriston Hospital, Swansea, Wales, United Kingdom|BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom|Renal and Urology Directorate, Leicester General Hospital, Leicester, United Kingdom","https://ClinicalTrials.gov/show/NCT01233869"
4,"Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Metformin|Other: Placebo","University of Maryland Medical Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT02656017"
5,"Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Tolvaptan","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Hudson, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Port Charlotte, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Wichita, Kansas, United States|Baton Rouge, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Greenbelt, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Kalamazoo, Michigan, United States|Pontiac, Michigan, United States|Roseville, Michigan, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Eatontown, New Jersey, United States|Voorhees, New Jersey, United States|Buffalo, New York, United States|Laurelton, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Bethlehem, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Orangeburg, South Carolina, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Burlington, Vermont, United States|Arlington, Virginia, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Wenatchee, Washington, United States|Morgantown, West Virginia, United States|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Junin, Buenos Aires, Argentina|Pergamino, Buenos Aires, Argentina|Pilar, Buenos Aires, Argentina|Córdoba, Argentina|Córdoba, Argentina|Córdoba, Argentina|Camperdown, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|St Leonards, New South Wales, Australia|Westmead, New South Wales, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Launceston, Tasmania, Australia|Parkville, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|Perth, Western Australia, Australia|Aalst, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Edegem, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liège, Belgium|Edmonton, Alberta, Canada|Mount Pearl, Newfoundland and Labrador, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Brno, Czechia|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Jilemnice, Czechia|Liberec, Czechia|Ostrava, Czechia|Praha 2, Czechia|Praha 4, Czechia|Aalborg, Denmark|Aarhus N, Denmark|Holstebro, Denmark|Heidelberg, Baden Wuerttemberg, Germany|Muenchen, Bayern, Germany|Nuernberg, Bayern, Germany|Wiesbaden, Hessen, Germany|Duesseldorf, Nordrhein Westfalen, Germany|Essen, Nordrhein Westfalen, Germany|Dresden, Sachsen, Germany|Berlin, Germany|Budapest, Hungary|Pecs, Hungary|Szeged, Hungary|Ashkelon, Israel|Jerusalem, Israel|Nahariya, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Montichiari, Brescia, Italy|Bari, Italy|Lecco, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Pavia, Italy|Amsterdam, Netherlands|Groningen, Netherlands|Nijmegen, Netherlands|Bergen, Norway|Ciechanow, Poland|Gdansk, Poland|Golub Dobrzyn, Poland|Krakow, Poland|Lodz, Poland|Lodz, Poland|Lublin, Poland|Szczecin, Poland|Warszawa, Poland|Wroclaw, Poland|Bucuresti, Romania|Bucuresti, Romania|Bucuresti, Romania|Oradea, Romania|Kemerovo, Russian Federation|Krasnoyarsk, Russian Federation|Saint-Petersburg, Russian Federation|Saint-Petersburg, Russian Federation|Yaroslavl, Russian Federation|Pretoria, Gauteng, South Africa|Durban, KwaZulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Barcelona, Spain|Ciudad Real, Spain|Madrid, Spain|Madrid, Spain|Valencia, Spain|Göteborg, Sweden|Linköping, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Belfast, County Antrim, United Kingdom|Exeter, Devon, United Kingdom|Hull, East Riding Of Yorkshire, United Kingdom|Brighton, East Sussex, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Salford, Greater Manchester, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Inverness, Highland Region, United Kingdom|Leicester, Leicestershire, United Kingdom|Edinburgh, Lothian Region, United Kingdom|Liverpool, Norfolk, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Stoke on Trent, Staffordshire, United Kingdom|Newcastle upon Tyne, Tyne & Wear, United Kingdom|Coventry, Warwickshire, United Kingdom|Birmingham, West Midlands, United Kingdom|Middlesbrough, United Kingdom|Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT02251275"
6,"Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Behavioral: Weight Loss","Kristen Nowak, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT03342742"
7,"A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: KD019 (tesevatinib)","UCLA Medical Center, Los Angeles, California, United States|University of Colorado Denver, Denver, Colorado, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New York University School of Medicine, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|University of Virginia - Nephrology Clinical Research Center, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT01559363"
8,"Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: pravastatin|Drug: Placebo","University of Colorado at Denver and Health Sciences Center, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT00456365"
9,"The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Polycystic Kidney, Autosomal Dominant","Behavioral: High Sodium Diet|Behavioral: Low Sodium Diet|Behavioral: Hypertonic saline infusion","Department of Medical Research, Holstebro Hospital, Holstebro, Denmark","https://ClinicalTrials.gov/show/NCT00410007"
10,"A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients","Terminated","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: Venglustat GZ402671|Drug: Placebo","Investigational Site Number 8400002, Birmingham, Alabama, United States|Investigational Site Number 8400017, Los Angeles, California, United States|Investigational Site Number 8400001, San Francisco, California, United States|Investigational Site Number 8400008, Aurora, Colorado, United States|Investigational Site Number 8400010, New Haven, Connecticut, United States|Investigational Site Number 8400004, Atlanta, Georgia, United States|Investigational Site Number 8400007, Chicago, Illinois, United States|Investigational Site Number 8400014, Iowa City, Iowa, United States|Investigational Site Number 8400003, Kansas City, Kansas, United States|Investigational Site Number 8400021, Baltimore, Maryland, United States|Investigational Site Number 8400016, Boston, Massachusetts, United States|Investigational Site Number 8400020, Rochester, Minnesota, United States|Investigational Site Number 8400027, Kansas City, Missouri, United States|Investigational Site Number 8400011, Philadelphia, Pennsylvania, United States|Investigational Site Number 8400015, San Antonio, Texas, United States|Investigational Site Number 8400019, Morgantown, West Virginia, United States|Investigational Site Number 8400005, Madison, Wisconsin, United States|Investigational Site Number 8400006, Milwaukee, Wisconsin, United States|Investigational Site Number 0320001, Buenos Aires, Argentina|Investigational Site Number 0320003, Santa Fe, Argentina|Investigational Site Number 0360002, Herston, Australia|Investigational Site Number 0360003, Nedlands, Australia|Investigational Site Number 0360001, Westmead, Australia|Investigational Site Number 0400001, Graz, Austria|Investigational Site Number 0400004, Wien, Austria|Investigational Site Number 0560001, Bruxelles, Belgium|Investigational Site Number 0560002, Leuven, Belgium|Investigational Site Number 1240002, Edmonton, Canada|Investigational Site Number 1240003, Montreal, Canada|Investigational Site Number 1240001, Toronto, Canada|Investigational Site Number 1560005, Beijing, China|Investigational Site Number 1560004, Chengdu, China|Investigational Site Number 1560009, Guangzhou, China|Investigational Site Number 1560006, Hangzhou, China|Investigational Site Number 1560002, Hefei, China|Investigational Site Number 1560007, Nanjing, China|Investigational Site Number 1560008, Nanjing, China|Investigational Site Number 1560001, Shanghai, China|Investigational Site Number 1560003, Shenyang, China|Investigational Site Number 2030001, Praha 2, Czechia|Investigational Site Number 2030002, Praha 4, Czechia|Investigational Site Number 2080001, Copenhagen, Denmark|Investigational Site Number 2080002, Roskilde, Denmark|Investigational Site Number 2500004, Bordeaux, France|Investigational Site Number 2500003, Brest, France|Investigational Site Number 2500002, Paris, France|Investigational Site Number 2500001, Toulouse, France|Investigational Site Number 2760001, Berlin, Germany|Investigational Site Number 2760002, Dresden, Germany|Investigational Site Number 2760010, Dresden, Germany|Investigational Site Number 2760007, Düsseldorf, Germany|Investigational Site Number 2760009, Essen, Germany|Investigational Site Number 2760005, Hannover, Germany|Investigational Site Number 2760003, Köln, Germany|Investigational Site Number 2760011, Leipzig, Germany|Investigational Site Number 2760012, Mainz, Germany|Investigational Site Number 2760004, München, Germany|Investigational Site Number 3760003, Ashdod, Israel|Investigational Site Number 3760002, Reẖovot, Israel|Investigational Site Number 3800001, Brescia, Italy|Investigational Site Number 3800002, Milano, Italy|Investigational Site Number 3800003, Napoli, Italy|Investigational Site Number 3920002, Bunkyo-Ku, Japan|Investigational Site Number 3920005, Kamakura-Shi, Japan|Investigational Site Number 3920006, Kawasaki-Shi, Japan|Investigational Site Number 3920010, Kyoto-Shi, Japan|Investigational Site Number 3920009, Nagoya-Shi, Japan|Investigational Site Number 3920003, Niigata-Shi, Japan|Investigational Site Number 3920007, Osaka-Shi, Japan|Investigational Site Number 3920001, Sapporo-Shi, Japan|Investigational Site Number 3920004, Shinjuku-Ku, Japan|Investigational Site Number 3920008, Toyoake-Shi, Japan|Investigational Site Number 4100001, Seoul, Korea, Republic of|Investigational Site Number 4100002, Seoul, Korea, Republic of|Investigational Site Number 5280003, Amsterdam, Netherlands|Investigational Site Number 5280001, Groningen, Netherlands|Investigational Site Number 5280002, Nijmegen, Netherlands|Investigational Site Number 6160003, Warszawa, Poland|Investigational Site Number 6160002, Wrocław, Poland|Investigational Site Number 6160001, Łódź, Poland|Investigational Site Number 6200004, Almada, Portugal|Investigational Site Number 6200005, Carnaxide, Portugal|Investigational Site Number 6200001, Loures, Portugal|Investigational Site Number 6420002, Bucuresti, Romania|Investigational Site Number 6420004, Oradea, Romania|Investigational Site Number 6420001, Timisoara, Romania|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240001, Barcelona, Spain|Investigational Site Number 7240002, Madrid / Madrid, Spain|Investigational Site Number 1580001, Taichung, Taiwan|Investigational Site Number 1580002, Taipei, Taiwan|Investigational Site Number 7920001, Istanbul, Turkey|Investigational Site Number 7920002, Kayseri, Turkey|Investigational Site Number 7920003, Kocaeli, Turkey|Investigational Site Number 8260001, Sheffield, United Kingdom","https://ClinicalTrials.gov/show/NCT03523728"
11,"Feasibility Study of Metformin Therapy in ADPKD","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Metformin|Drug: Placebo","University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT02903511"
12,"Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Tolvaptan","University of Colorado, Denver, Colorado, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Univerisity of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Davita Clinical Research, Minneapolis, Minnesota, United States|Mayo Medical Center, Rochester, Minnesota, United States|Rogosin Institute, New York, New York, United States|Northwest Renal Clinic, Portland, Oregon, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Nephrology Clinical Research Center at the University of Virginia, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT00413777"
13,"The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Polycystic Kidney, Autosomal Dominant|Chronic Kidney Diseases","Other: Fluid intake|Other: Thirsting","Department of Medical Research, Regional Hospital Holstebro, Holstebro, Denmark","https://ClinicalTrials.gov/show/NCT04363554"
14,"A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease","Not yet recruiting","No Results Available","Autosomal Dominant Polycystic Kidney Disease|ADPKD|Polycystic Kidney, Autosomal Dominant","Drug: RGLS8429|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT05521191"
15,"Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD","Completed","No Results Available","Polycystic Kidney, Autosomal Dominant","Drug: Tolvaptan|Drug: Placebo","Departments of medical research and medicine, Holstebro, Denmark","https://ClinicalTrials.gov/show/NCT03803124"
16,"Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease","Enrolling by invitation","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Pravastatin|Drug: sodium citrate","Keck School of Medicine of University of Southern California, Los Angeles, California, United States","https://ClinicalTrials.gov/show/NCT04284657"
17,"To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers and Autosomal Dominant Polycystic Kidney Disease Subjects","Active, not recruiting","No Results Available","Autosomal Dominant Polycystic Kidney","Drug: AL01211 or Placebo (Part A)|Drug: AL01211 or Placebo (Part B)","Nucleus Network, Melbourne, Victoria, Australia","https://ClinicalTrials.gov/show/NCT04908462"
18,"A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Autosomal Dominant Polycystic Kidney","Other: High Water Intake","The Rogosin Institute, New York, New York, United States","https://ClinicalTrials.gov/show/NCT03102632"
19,"Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease","Unknown status","No Results Available","Autosomal Dominant Polycystic Kidney","Drug: Tolvaptan","Aarhus University Hospital - Site 43, Skejby, Aarhus N, Denmark|Odense University Hospital - Site 45, Odense, Odense C, Denmark|Rigshospitalet - Site 42, Copenhagen, Denmark|Herlev Hospital, Herlev, Denmark|Nordsjaellands Hospital - Site 41, Hillerød, Denmark|Sjællands University Hospital Roskilde, Roskilde, Denmark","https://ClinicalTrials.gov/show/NCT03596957"
20,"Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD","Completed","Has Results","Polycystic Kidney, Autosomal Dominant","Drug: Curcumin|Other: Placebo","University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT02494141"
21,"A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Active, not recruiting","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Placebo|Drug: GLPG2737","Cliniques Universitaires St. Luc (UCL), Brussels, Belgium|UZ Leuven, Leuven, Belgium|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Králové, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, Czechia|Uniklinikum Dresden, Dresden, Germany|IRCSS Ospedale San Raffaele, Milan, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Uni Campania L. Vanvitelli, Napoli, Italy|Fondazione Salvatore Maugeri IRCCS, Pavia, Italy|Amsterdam UMC, Amsterdam, Netherlands|UMCG, Groningen, Netherlands|Radboud UMC, Nijmegen, Netherlands|Specjalistyczne Centrum Medyczne SCM Spółka z o.o., Kraków, Poland|DaVita Sp. z o.o. Stacja Dializ, Warsaw, Poland|Szpital Kliniczny UM w Lodzi, Łódź, Poland|Fundacion Puigvert, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Nefrologia Clinica C.P., Madrid, Spain|Hospital Universitario Dr. Peset, Valencia, Spain","https://ClinicalTrials.gov/show/NCT04578548"
22,"The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Lixivaptan","Palladio Biosciences Clinical Site, Los Angeles, California, United States|Palladio Biosciences Clinical Site, Jacksonville, Florida, United States|Palladio Biosciences Clinical Site, Miami, Florida, United States|Palladio Biosciences Clinical Site, Miami, Florida, United States|Palladio Biosciences Clinical Site, Palmetto Bay, Florida, United States|Palladio Biosciences Clinical Site, Tampa, Florida, United States|Palladio Biosciences Clinical Site, Baltimore, Maryland, United States|Palladio Biosciences Clinical Site, Rochester, Minnesota, United States|Palladio Biosciences Clinical Site, Kansas City, Missouri, United States|Palladio Biosciences Clinical Site, Laurelton, New York, United States|Palladio Biosciences Clinical Site, Indiana, Pennsylvania, United States|Palladio Biosciences Clinical Site, Nashville, Tennessee, United States|Palladio Biosciences Clinical Site, Salt Lake City, Utah, United States","https://ClinicalTrials.gov/show/NCT03487913"
23,"8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan MR|Drug: Tolvaptan IR|Drug: Placebo","Otsuka Investigational Site, Huntsville, Alabama, United States|Otsuka Investigational Site, Mobile, Alabama, United States|Otsuka Investigational Site, Peoria, Arizona, United States|Otsuka Investigational Site, Tempe, Arizona, United States|Otsuka Investigational Site, Los Angeles, California, United States|Otsuka Investigational Site, San Diego, California, United States|Otsuka Investigational Site 2, Aurora, Colorado, United States|Otsuka Investigational Site, Aurora, Colorado, United States|Otsuka Investigational Site, Denver, Colorado, United States|Otsuka Investigational Site, New Haven, Connecticut, United States|Otsuka Investigational Site, Jacksonville, Florida, United States|Otsuka Investigational Site, Melbourne, Florida, United States|Otsuka Investigational Site, Atlanta, Georgia, United States|Otsuka Investigational Site, Augusta, Georgia, United States|Otsuka Investigational Site, Peoria, Illinois, United States|Otsuka Investigational Site, Mishawaka, Indiana, United States|Otsuka Investigational Site, Kansas City, Kansas, United States|Otsuka Investigational Site, Paducah, Kentucky, United States|Otsuka Investigational Site, Shreveport, Louisiana, United States|Otsuka Investigational Site, Baltimore, Maryland, United States|Otsuka Investigational Site, Rockville, Maryland, United States|Otsuka Investigational Site, Boston, Massachusetts, United States|Otsuka Investigational Site, Detroit, Michigan, United States|Otsuka Investigational Site, Rochester, Minnesota, United States|Otsuka Investigational Site, Voorhees, New Jersey, United States|Otsuka Investigational Site, Buffalo, New York, United States|Otsuka Investigational Site, Chapel Hill, North Carolina, United States|Otsuka Investigational Site, Cleveland, Ohio, United States|Otsuka Investigational Site, Bethlehem, Pennsylvania, United States|Otsuka Investigational Site, Philadelphia, Pennsylvania, United States|Otsuka Investigational Site, Anderson, South Carolina, United States|Otsuka Investigational Site, Nashville, Tennessee, United States|Otsuka Investigational Site, Arlington, Texas, United States|Otsuka Investigational Site, Mission, Texas, United States|Otsuka Investigational Site, Charlottesville, Virginia, United States","https://ClinicalTrials.gov/show/NCT01451827"
24,"Adrenal Functions in Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Tetracosactin","Istanbul Univetsity, Istanbul Medical Faculty, Department of Internal Medicine, Istanbul, Turkey","https://ClinicalTrials.gov/show/NCT00598377"
25,"Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: Placebo|Drug: Everolimus","Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Nantes Cedex, France|Novartis Investigative Site, Paris cedex 15, France|Novartis Investigative Site, Toulouse Cedex 4, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt am Main, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Lübeck, Germany|Novartis Investigative Site, Muenster, Germany|Novartis Investigative Site, Regensburg, Germany|Novartis Investigative Site, Würzburg, Germany","https://ClinicalTrials.gov/show/NCT00414440"
26,"Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Phase A Tolvaptan|Drug: Placebo Phase A|Drug: Phase B Tolvaptan","Gent, Oost-Vlaanderen, Belgium|Leuven, Vlaams Brabant, Belgium|Brussels, Belgium|Bruxelles, Belgium|Montegnee, Belgium|Cologne, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Leipzig, Germany|Tuebingen, Germany|Milano, Italy|Napoli, Italy|Napoli, Italy|Pavia, Italy|Birmingham, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Nottingham, United Kingdom","https://ClinicalTrials.gov/show/NCT02964273"
27,"The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain","Withdrawn","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Device: Vessix",,"https://ClinicalTrials.gov/show/NCT02746419"
28,"Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Tolvaptan","Inje University Busan Paik Hospital, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Kyungpook National University Hospital, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Hallym University Medical Center, Pyeongchon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Hanyang University Seoul Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of","https://ClinicalTrials.gov/show/NCT03949894"
29,"Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency","Terminated","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Sirolimus|Drug: conventional therapy","Mario Negri Institute - Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT01223755"
30,"Treatment of Vascular Stiffness in ADPKD","Recruiting","No Results Available","Autosomal Dominant Polycystic Kidney","Dietary Supplement: Sodium chloride (NaCl)|Dietary Supplement: Placebo|Drug: Amiloride Hcl 5mg Tab","Erasmus University Medical Centre Rotterdam, Rotterdam, South-Holland, Netherlands","https://ClinicalTrials.gov/show/NCT05228574"
31,"Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Other: Water prescription","University of Kansas Medical Center, Kansas City, Kansas, United States","https://ClinicalTrials.gov/show/NCT00759369"
32,"Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Sirolimus|Other: Standard","University Hospital, Zurich, Switzerland","https://ClinicalTrials.gov/show/NCT00346918"
33,"Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan","University Medical Center Groningen, Groningen, Netherlands","https://ClinicalTrials.gov/show/NCT01336972"
34,"Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Unknown status","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Triptolide-Containing Formulation|Drug: Placebo","Shanghai Changzheng Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT02115659"
35,"A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: OPC-41061","Kanto Region, Japan","https://ClinicalTrials.gov/show/NCT01022424"
36,"A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: OPC-41061","Kanto Region, Japan","https://ClinicalTrials.gov/show/NCT00841568"
37,"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Octreotide-LAR|Other: Saline solution.","Ospedale San giovanni di Dio, Agrigento, AG, Italy|Clinical Research Center fo Rare Diseases Aldo and Cele Daccò, Ranica, Bergamo, Italy|Hospital ""Vito Fazzi"", Lecce, Italy|Hospital ""Ospedale Maggiore policlinico, Mangiagalli e Regina elena"", Milan, Italy|University ""Federico II"", Naples, Italy|Ospedale Cà Foncello, Treviso, Italy","https://ClinicalTrials.gov/show/NCT01377246"
38,"A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease （ADPKD)","Drug: tolvaptan","Chubu Region, Japan|Chugoku Region, Japan|Hokkaido Region, Japan|Kanto Region, Japan|Kinki Region, Japan|Kyushu Region, Japan|Tohoku Region, Japan","https://ClinicalTrials.gov/show/NCT01280721"
39,"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Chronic Kidney Disease|Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan (OPC-41061)|Drug: Placebo","Birmingham, Alabama, United States|Huntsville, Alabama, United States|Mobile, Alabama, United States|Phoenix, Arizona, United States|Tempe, Arizona, United States|Tucson, Arizona, United States|La Jolla, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|Hudson, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Port Charlotte, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Meridian, Idaho, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Wichita, Kansas, United States|Baton Rouge, Louisiana, United States|Lafayette, Louisiana, United States|Baltimore, Maryland, United States|Greenbelt, Maryland, United States|Rockville, Maryland, United States|Wheaton, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Kalamazoo, Michigan, United States|Pontiac, Michigan, United States|Roseville, Michigan, United States|Minneapolis, Minnesota, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Las Vegas, Nevada, United States|Reno, Nevada, United States|Eatontown, New Jersey, United States|Voorhees, New Jersey, United States|Buffalo, New York, United States|Mineola, New York, United States|New York, New York, United States|New York, New York, United States|New York, New York, United States|Rosedale, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Winston-Salem, North Carolina, United States|Fargo, North Dakota, United States|Grand Forks, North Dakota, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Bethlehem, Pennsylvania, United States|Doylestown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Orangeburg, South Carolina, United States|Knoxville, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Houston, Texas, United States|Houston, Texas, United States|McAllen, Texas, United States|Burlington, Vermont, United States|Arlington, Virginia, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Wenatchee, Washington, United States|Morgantown, West Virginia, United States|La Crosse, Wisconsin, United States|Bahia Blanca, Buenos Aires, Argentina|Ciudad Autonoma, Buenos Aires, Argentina|Ciudad Autonoma, Buenos Aires, Argentina|Ciudad Autonoma, Buenos Aires, Argentina|Ciudad Autonoma, Buenos Aires, Argentina|Ciudad Autonoma, Buenos Aires, Argentina|Junin, Buenos Aires, Argentina|Pergamino, Buenos Aires, Argentina|Pilar, Buenos Aires, Argentina|Sarandi, Buenos Aires, Argentina|Cordoba, Argentina|Cordoba, Argentina|Cordoba, Argentina|Camperdown, New South Wales, Australia|Concord, New South Wales, Australia|New Lambton Heights, New South Wales, Australia|St. Leonards, New South Wales, Australia|Westmead, New South Wales, Australia|Woolloongabba, Queensland, Australia|Adelaide, South Australia, Australia|Launceston, Tasmania, Australia|Parkville, Victoria, Australia|Reservoir, Victoria, Australia|Richmond, Victoria, Australia|Perth, Western Australia, Australia|Aalst, Belgium|Antwerpen, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Gent, Belgium|Kortrijk, Belgium|Leuven, Belgium|Liège, Belgium|Edmonton, Alberta, Canada|St. John's, Newfoundland and Labrador, Canada|Scarborough, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Montréal, Quebec, Canada|Brno, Czechia|Ceske Budejovice, Czechia|Hradec Kralove, Czechia|Jihlava, Czechia|Jilemnice, Czechia|Liberec, Czechia|Ostrava, Czechia|Praha 2, Czechia|Praha 4, Czechia|Tabor, Czechia|Aalborg, Denmark|Aarhus C, Denmark|Holstebro, Denmark|Odense C, Denmark|Viborg, Denmark|Brest cedex 2, Finistere, France|Bordeaux Cedex, Gironde, France|Toulouse Cedex 9, Haute Garonne, France|Montpellier cedex 5, Herault, France|Grenoble cedex 9, Isere, France|Saint-Priest-En-Jarez, Loire, France|Reims Cedex, Marne, France|Vandoeuvre les Nancy, Meurthe Et Moselle, France|Lyon Cedex 03, Rhone, France|Pierre-Bénite cedex, Rhone, France|Heidelberg, Baden Wuerttemberg, Germany|Muenchen, Bayern, Germany|Nuernberg, Bayern, Germany|Hannover, Niedersachsen, Germany|Duesseldorf, Nordrhein Westfalen, Germany|Essen, Nordrhein Westfalen, Germany|Wiesbaden, Nordrhein Westfalen, Germany|Dresden, Sachsen, Germany|Budapest, Hungary|Pecs, Hungary|Szeged, Hungary|Ashkelon, Israel|Jerusalem, Israel|Nahariya, Israel|Petach Tikva, Israel|Petaẖ Tiqwa, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Torrette Di Ancona, Ancona, Italy|Montichiari, Brescia, Italy|Bari, Italy|Bologna, Italy|Lecco, Italy|Milano, Italy|Milano, Italy|Modena, Italy|Napoli, Italy|Pavia, Italy|Groningen, Netherlands|Nijmegen, Netherlands|Bergen, Norway|Oslo, Norway|Stavanger, Norway|Ciechanow, Poland|Golub Dobrzyn, Poland|Kraków, Poland|Lodz, Poland|Lublin, Poland|Warszawa, Poland|Wroclaw, Poland|Łódź, Poland|San Juan, Puerto Rico|Bucuresti, Romania|Bucuresti, Romania|Oradea, Romania|Krasnoyarsk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Pretoria, Gauteng, South Africa|Durban, KwaZulu-Natal, South Africa|Cape Town, Western Cape, South Africa|L'Hospitalet de Llobregat, Barcelona, Spain|Ciudad Real, Spain|Madrid, Spain|Madrid, Spain|Sevilla, Spain|Sevilla, Spain|Valencia, Spain|Göteborg, Sweden|Linköping, Sweden|Stockholm, Sweden|Stockholm, Sweden|Uppsala, Sweden|Örebro, Sweden|Exeter, Devon, United Kingdom|Hull, East Riding Of Yorkshire, United Kingdom|Brighton, East Sussex, United Kingdom|London, Greater London, United Kingdom|Manchester, Greater Manchester, United Kingdom|Salford, Greater Manchester, United Kingdom|Stevenage, Hertfordshire, United Kingdom|Inverness, Highland Region, United Kingdom|Leicester, Leicestershire, United Kingdom|Edinburgh, Lothian Region, United Kingdom|Liverpool, Merseyside, United Kingdom|Middlesbrough, North Yorkshire, United Kingdom|Sheffield, South Yorkshire, United Kingdom|Stoke-on-Trent, Staffordshire, United Kingdom|Newcastle upon Tyne, Tyne & Wear, United Kingdom|Coventry, Warwickshire, United Kingdom|Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT02160145"
40,"Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease","Terminated","No Results Available","Autosomal Dominant Polycystic Kidney|ADPKD","Drug: Lixivaptan|Drug: Placebo","Nephrology Associates, PC - Greystone, Hoover, Alabama, United States|Nephrology Consultants, LLC, Huntsville, Alabama, United States|Arizona Kidney Disease & Hypertension Center - Scottsdale / Pima, Scottsdale, Arizona, United States|JEM Research Institute, Atlantis, Florida, United States|Elixia at Florida Kidney Physicians - Southeast, Fort Lauderdale, Florida, United States|Qway Research, Hialeah, Florida, United States|South Florida Nephrology Associates PA, Lauderdale Lakes, Florida, United States|Total Research Group, LLC, Miami, Florida, United States|Innovation Medical Research Center, Inc, Palmetto Bay, Florida, United States|Florida Kidney Physicians - Tampa, Tampa, Florida, United States|Clinical Site Partners, LLC, Winter Park, Florida, United States|Tufts Medical Center, Inc,, Boston, Massachusetts, United States|St Clair Nephrology Research, LLC, Roseville, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Angel City Research, Inc, Morrisville, North Carolina, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|Brown Medicine - Brown Physicians Patient Center, Riverside, Rhode Island, United States|Knoxville Kidney Center LLC, Knoxville, Tennessee, United States|Prolato Clinical Research Center (PCRC), Houston, Texas, United States|Clinical Advancement Center, PLLC, San Antonio, Texas, United States|Utah Kidney Research Insistute, Salt Lake City, Utah, United States|Nephrology Associates of Northern Virginia, Inc, Fairfax, Virginia, United States|Renal Research - Gosford, Gosford, New South Wales, Australia|University Multiprofile Hospital for Active Treatment, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment - Kaspela, Plovdiv, Bulgaria|Medical Center ""Hipokrat - N"", Plovdiv, Bulgaria|Kidney Center - Medical Center, Varna, Bulgaria|Multi-Profile Hospital for Active Treatment Sveta Anna - Varna, Varna, Bulgaria|Bajai Szent Rokus Korhaz, Baja, Hungary|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|Bugat Pal Korhaz, Gyöngyös, Hungary|University of Pecs, Pécs, Hungary|SCM Spolka z o.o, Kraków, Poland|Provita Centrum Medyczne sp. z o.o., Warsaw, Poland|Hospital Universitari de Bellvitge (HUB), Barcelona, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|T.R. Ministry of Health Ankara Training and Research Hospital (Internal Disease, Division of Nephrology), Ankara, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Fatih, Turkey|Istanbul Universitesi - Cerrahpasa Tip Fakultesi Hastanesi (IUCTFH), Fatih, Turkey|Erciyes Universitesi Tip Fakultesi (Erciyes University Faculty of Medicine) (Internal Medicine; Nephrology), Kayseri, Turkey|Salford Royal NHS Foundation Trust, Salford, United Kingdom","https://ClinicalTrials.gov/show/NCT04064346"
41,"Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy","Terminated","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: Rapamycin|Other: Standard of Care-Placebo","Yale Center for Clinical Investigation, New Haven, Connecticut, United States","https://ClinicalTrials.gov/show/NCT00920309"
42,"Efficacy of Tolvaptan on ADPKD Patients","Unknown status","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan","Kyorin University Hospital, Mitaka, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT02729662"
43,"Effects of Somatostatin on Liver in ADPKD","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: octeotride|Drug: placebo",,"https://ClinicalTrials.gov/show/NCT02119052"
44,"Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Behavioral: Diet and water adjustment","Tufts Medical Center, Boston, Massachusetts, United States","https://ClinicalTrials.gov/show/NCT02225860"
45,"Effect of the Aquaretic Tolvaptan on Nitric Oxide System","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan|Drug: Placebo","Department of Medical Research and Medicine, Holstebro Regional Hospital, Holstebro, Denmark","https://ClinicalTrials.gov/show/NCT02527863"
46,"Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan MR|Drug: Tolvaptan IR","Tufts-New England Medical Center, Boston, Massachusetts, United States|Davita Clinical Research, Minneapolis, Minnesota, United States|Mayo Medical Center, Rochester, Minnesota, United States|University Hospitals of Cleveland/Case, Cleveland, Ohio, United States|Northwest Renal Clinic Inc., Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT01210560"
47,"The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Everolimus|Drug: Calcineurin inhibitors maintenance","Bicêtre Hospital, Le Kremlin-Bicêtre, France","https://ClinicalTrials.gov/show/NCT02134899"
48,"Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101","Terminated","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: tesevatinib","UCLA Medical Center, Los Angeles, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cleveland Clinic, Cleveland, Ohio, United States|University of Virginia - Nephrology Clinical Research Center, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT02616055"
49,"Effect of Venglustat in Patients With Renal Impairment","Completed","No Results Available","Healthy Volunteers|Polycystic Kidney, Autosomal Dominant","Drug: Venglustat GZ/SAR402671","Investigational Site Number 8400001, Miami, Florida, United States","https://ClinicalTrials.gov/show/NCT03687554"
50,"Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease","Recruiting","No Results Available","Autosomal Dominant Polycystic Kidney|Hypertension|Endothelial Dysfunction","Dietary Supplement: Beetroot juice|Dietary Supplement: Nitrate-depleted beetroot juice","Westmead Hospital, Sydney, New South Wales, Australia|Westmead Institute for Medical Research, Westmead, New South Wales, Australia","https://ClinicalTrials.gov/show/NCT05401409"
51,"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Long-acting somatostatin|Other: Saline solution","Hospital ""Ospedali Riuniti"" Unit of Nephrology and Dialysis, Bergamo, Italy|Hospital ""V. Fazzi"" - Unit of neprology and Dialysis, Lecce, Italy|Hospital ""Presidio Osp. Maggiore Policlinico"", Milan, Italy|University ""Federico II"" of Naples, Napoli, Italy|Hospital Cà Foncello, Treviso, Italy","https://ClinicalTrials.gov/show/NCT00309283"
52,"A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON","Recruiting","No Results Available","Autosomal Dominant Polycystic Kidney|ADPKD","Drug: Bardoxolone methyl oral capsule|Drug: Placebo oral capsule","University of Alabama at Birmingham, Birmingham, Alabama, United States|Nephrology Associates PC, Homewood, Alabama, United States|Nephrology Consultants, LLC, Huntsville, Alabama, United States|AKDHC, Glendale, Arizona, United States|Aventiv Research, Inc, Mesa, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Rancho Research Institute, Downey, California, United States|California Institute of Renal Research, El Centro, California, United States|California Institute Renal Research, La Mesa, California, United States|University of California, Los Angeles, Los Angeles, California, United States|Keck USC/LAC, Los Angeles, California, United States|Amicis Research Center, Northridge, California, United States|Stanford University, Palo Alto, California, United States|Apex Research of Riverside, Riverside, California, United States|University of California San Francisco, San Francisco, California, United States|Western Nephrology, Arvada, Colorado, United States|University of Colorado Anschutz Medical Center, Aurora, Colorado, United States|Kidney Associates of Colorado, Denver, Colorado, United States|Denver Nephrologist, PC, Denver, Colorado, United States|Western Nephrology and Mineral Bone Disease, PC, Westminster, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Pro-Care Research Center, Corp., Miami Gardens, Florida, United States|University of Miami, Miami, Florida, United States|Discovery Medical Research Group, Ocala, Florida, United States|Innovation Medical Research Center, Inc, Palmetto Bay, Florida, United States|Volunteer Medical Research, Port Charlotte, Florida, United States|University of South Florida, Tampa, Florida, United States|Florida Premier Research Institute, LLC, Winter Park, Florida, United States|Emory University, Atlanta, Georgia, United States|Georgia Nephrology, LLC, Lawrenceville, Georgia, United States|Boise Kidney & Hypertension, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension, PLLC, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States|Ascension Via Christi Research, Wichita, Kansas, United States|Kansas Nephrology Research Institute, LLC, Wichita, Kansas, United States|Renal Associates of Baton Rouge, Baton Rouge, Louisiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|KidneyCare and Tranplant Services of New England, Springfield, Massachusetts, United States|Renal and Transplant Associates of New England, PC, Springfield, Massachusetts, United States|Paragon Health PC d/b/a Nephrology Center PC, Kalamazoo, Michigan, United States|Michigan Kidney Consultants, Pontiac, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|KSOSN, Las Vegas, Nevada, United States|UBMD - Nephrology Division, Buffalo, New York, United States|Nephrology Associates, P.C., Flushing, New York, United States|Division of Kidney Diseases and Hypertension, Great Neck, New York, United States|NYU Winthrop Hospital, Mineola, New York, United States|Mountain Kidney & Hypertension Associates, Asheville, North Carolina, United States|Metrolina Nephrology Associates, Charlotte, North Carolina, United States|North Carolina Nephrology, P.A. 2nd Floor, Raleigh, North Carolina, United States|Brookview Hills Research Associates, LLC, Winston-Salem, North Carolina, United States|Cincinnati VA Medical Center, Cincinnati, Ohio, United States|University of Cincinnati College of Medicine, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Columbia Nephrology Associates, PA, Columbia, South Carolina, United States|Nephrology Associates, P.C., Nashville, Tennessee, United States|TTUHSC, Amarillo, Texas, United States|Arlington Nephrology, PA, Arlington, Texas, United States|Research Management, Inc., Austin, Texas, United States|Research Management, Inc., Austin, Texas, United States|Houston Nephrology Research Partnership, Cypress, Texas, United States|Liberty Research Center, Dallas, Texas, United States|Renal Disease Research Institute, Dallas, Texas, United States|Davita Clinical Research, El Paso, Texas, United States|DaVita Med Center, Houston, Texas, United States|Clinical Advancement Center, San Antonio, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Nephrology Associates of Northern Virginia, Inc., Fairfax, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Milwaukee Nephrologists, SC, Wauwatosa, Wisconsin, United States|Renal Research, Gosford, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Westmead Hospital, Sydney, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Melbourne Health, Parkville, Victoria, Australia|Melbourne Renal Research Group, Reservoir, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Nephrology, Cliniques U St-Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel (VUB), Brussels, Belgium|University Hospitals Leuven, Dept. of Nephrology, Dialysis and Renal Transplantation, Leuven, Belgium|Chu Liege, Liège, Belgium|FN Brno, Brno, Czechia|Nephrology Dept., General Teaching Hospital, Prague, Czechia|IKEM, Praha, Czechia|University Hospital La Cavale Blanche, Brest, France|Chu Grenoble Alpes, Grenoble, France|Hospital Henri-Mondor AP-HP, Le Kremlin-Bicêtre, France|CHU de Nantes, Nantes, France|Hopital Necker, Universite Paris Descartes, Paris, France|Universitätsklinikum Erlangen, Med4, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover, Hanover, Germany|Klinikum rechts der Isar der TU München, München, Germany|Renal Division, ASST Santi Paolo e Carlo, Milan, Italy|Università di Modena e Reggio Emilia, Modena, Italy|Università della Campania L. Vanvitelli, Napoli, Italy|ICS Maugeri SpA SB, Pavia, Italy|Fondazione Policlinico Gemelli, Roma, Italy|Hokkaido University Hospital, Hokkaido, Japan|Toranomon Hospital Kajigaya, Kanagawa, Japan|Japan Community Healthcare Organization Sendai Hospital, Miyagi, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital, Osaka, Japan|Osaka City University Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Toranomon Hospital, Tokyo, Japan|Juntendo University Hospital, Tokyo, Japan|Tokyo Women's Medical University Hospital, Tokyo, Japan|Hospital Universitario de Badajoz, Badajoz, Spain|Hospital Del Mar, Barcelona, Spain|Fundacio Puigvert, Barcelona, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital Lucus Augusti, Lugo, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Getafe, Madrid, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Dr Peset, Valencia, Spain|North Bristol NHS Trust, Bristol, United Kingdom|Manchester University NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|Morriston Hospital, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT03918447"
53,"Tolvaptan Extension Study in Participants With ADPKD","Completed","Has Results","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Tolvaptan","Otsuka Investigational Site, Mobile, Alabama, United States|Otsuka Investigational Site, Peoria, Arizona, United States|Otsuka Investigational Site, Tempe, Arizona, United States|Otsuka Investigational Site, Los Angeles, California, United States|Otsuka Investigational Site, Palo Alto, California, United States|Otsuka Investigational Site, San Diego, California, United States|Otsuka Investigational Site, Aurora, Colorado, United States|Otsuka Investigational Site, New Haven, Connecticut, United States|Otsuka Investigational Site, Jacksonville, Florida, United States|Otsuka Investigational Site, Port Charlotte, Florida, United States|Otsuka Investigational Site, Atlanta, Georgia, United States|Otsuka Investigational Site, Augusta, Georgia, United States|Otsuka Investigational Site, Chicago, Illinois, United States|Otsuka Investigational Site, Kansas City, Kansas, United States|Otsuka Investigational Site, Baton Rouge, Louisiana, United States|Otsuka Investigational Site, Baltimore, Maryland, United States|Otsuka Investigational Site, Rockville, Maryland, United States|Otsuka Investigational Site, Boston, Massachusetts, United States|Otsuka Investigational Site, Detroit, Michigan, United States|Otsuka Investigational Site, Minneapolis, Minnesota, United States|Otsuka Investigational Site, Rochester, Minnesota, United States|Otsuka Investigational Site, Voorhees, New Jersey, United States|Otsuka Investigational Site, Buffalo, New York, United States|Otsuka Investigational Site, Hawthorne, New York, United States|Otsuka Investigational Site, New York, New York, United States|Otsuka Investigational Site, New York, New York, United States|Otsuka Investigational Site, Chapel Hill, North Carolina, United States|Otsuka Investigational Site, Cincinnati, Ohio, United States|Otsuka Investigational Site, Cleveland, Ohio, United States|Otsuka Investigational Site, Portland, Oregon, United States|Otsuka Investigational Site, Bethlehem, Pennsylvania, United States|Otsuka Investigational Site, Philadelphia, Pennsylvania, United States|Otsuka Investigational Site, Anderson, South Carolina, United States|Otsuka Investigational Site, Nashville, Tennessee, United States|Otsuka Investigational Site, Nashville, Tennessee, United States|Otsuka Investigational Site, Arlington, Texas, United States|Otsuka Investigational Site, McAllen, Texas, United States|Otsuka Investigational Site, Charlottesville, Virginia, United States|Otsuka Investigational Site, C.a.b.a., Buenos Aires, Argentina|Otsuka Investigational Site, Pilar, Buenos Aires, Argentina|Otsuka Investigational Site, Buenos Aires, Argentina|Otsuka Investigational Site, Cordoba, Argentina|Otsuka Investigational Site, Córdoba, Argentina|Otsuka Investigational Site, St. Leonards, New South Wales, Australia|Otsuka Investigational Site, Westmead, New South Wales, Australia|Otsuka Investigational Site, Woolloongabba, Queensland, Australia|Otsuka Investigational Site, Adelaide, South Australia, Australia|Otsuka Investigational Site, Parkville, Victoria, Australia|Otsuka Investigational Site, Perth, Western Australia, Australia|Otsuka Investigational Site, Brussels, Belgium|Otsuka Investigational Site, Brussels, Belgium|Otsuka Investigational Site, Gent, Belgium|Otsuka Investigational Site, Halifax, Nova Scotia, Canada|Otsuka Investigational Site, Montreal, Quebec, Canada|Otsuka Investigational Site, Montreal, Quebec, Canada|Otsuka Investigational Site, Bordeaux, France|Otsuka Investigational Site, Caen Cedex, France|Otsuka Investigational Site, Lyon Cedex 3, France|Otsuka Investigational Site, Paris, France|Otsuka Investigational Site, Reims Cedex, France|Otsuka Investigational Site, Saint-Etienne Cedex 2, France|Otsuka Investigational Site, Toulouse Cedex 09, France|Otsuka Investigational Site, Dresden, Germany|Otsuka Investigational Site, Dusseldorf, Germany|Otsuka Investigational Site, Essen, Germany|Otsuka Investigational Site, Heidelberg, Germany|Otsuka Investigational Site, Nurnberg, Germany|Otsuka Investigational Site, Bergamo, Italy|Otsuka Investigational Site, Milano, Italy|Otsuka Investigational Site, Modena, Italy|Otsuka Investigational Site, Napoli, Italy|Otsuka Investigational Site, Pavia, Italy|Otsuka Investigational Site, Amsterdam, Netherlands|Otsuka Investigational Site, Groningen, Netherlands|Otsuka Investigational Site, Ciechanów, Poland|Otsuka Investigational Site, Krakow, Poland|Otsuka Investigational Site, Lodz, Poland|Otsuka Investigational Site, Lublin, Poland|Otsuka Investigational Site, Szczecin, Poland|Otsuka Investigational Site, Warszawa, Poland|Otsuka Investigational Site, Wrocław, Poland|Otsuka Investigational Site, Bucuresti, Romania|Otsuka Investigational Site, Bucuresti, Romania|Otsuka Investigational Site, Iasi, Romania|Otsuka Investigational Site, Kemerovo, Russian Federation|Otsuka Investigational Site, St. Petersburg, Russian Federation|Otsuka Investigational Site, Tomsk, Russian Federation|Otsuka Investigational Site, Belfast, United Kingdom|Otsuka Investigational Site, Birmingham, United Kingdom|Otsuka Investigational Site, Brighton, United Kingdom|Otsuka Investigational Site, Coventry, United Kingdom|Otsuka Investigational Site, Edinburgh, United Kingdom|Otsuka Investigational Site, Inverness, United Kingdom|Otsuka Investigational Site, London, United Kingdom|Otsuka Investigational Site, London, United Kingdom|Otsuka Investigational Site, London, United Kingdom|Otsuka Investigational Site, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT01214421"
54,"Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Other: Blood Collection","CHU Angers, Angers, France|AUB Brest, Brest, France|Centre de néphrologie et de dialyse d'Armorique, Brest, France|CHRU Brest, Brest, France|CH Laval, Laval, France|CH du Mans, Le Mans, France|ECHO dialyse, Le Mans, France|Centre de dialyse de Lorient, Lorient, France|CH Bretagne Sud, Lorient, France|Hôpital Hôtel Dieu - CHU Nantes, Nantes, France|CH Niort, Niort, France|ECHO les Sables d'Olonne, Olonne sur Mer, France|Hôpital Jean Bernard - CHU Poitiers, Poitiers, France|CHCB site de Noyal Pontivy, Pontivy, France|CH Laënnec, Quimper, France|AUB Santé, Quimper, France|Hôpital Pontchaillou, Rennes, France|Echo Csmn, Rezé, France|Centre de Pérharidy, Roscoff, France|Hôpital Yves Le Foll, Saint Brieuc, France|ECHO Centre Ambulatoire, Saint Herblain, France|CH Saint Malo, Saint Malo, France|CH de Saint Nazaire, Saint Nazaire, France|Hôpital Bretonneau - CHU Tours, Tours, France|CH Bretagne Atlantique - Site de Vannes, Vannes, France","https://ClinicalTrials.gov/show/NCT02112136"
55,"Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease","Unknown status","No Results Available","Adult Polycystic Kidney Disease","Procedure: renal denervation","Department of Nephrology, Odense, Denmark","https://ClinicalTrials.gov/show/NCT02062671"
56,"High Water Intake in Polycystic Kidney Disease","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Dietary Supplement: High water intake|Other: Ad libitum water intake","Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom","https://ClinicalTrials.gov/show/NCT02933268"
57,"Effects of Somatostatin on ADPKD Heart","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease|Glomerular Filtration Rate > 40 ml/Min","Drug: Octeotride|Drug: Placebo",,"https://ClinicalTrials.gov/show/NCT02119013"
58,"Lanreotide In Polycystic Kidney Disease Study","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD","Drug: Lanreotide|Drug: saline","Necker hospital, Paris, France","https://ClinicalTrials.gov/show/NCT02127437"
59,"Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD","Completed","No Results Available","Autosomal Dominant Polycystic Kidney|ADPKD","Drug: Tesevatinib|Drug: Placebo","University of California San Diego, La Jolla, California, United States|California Institute for Renal Research, La Mesa, California, United States|University of California Los Angeles, Los Angeles, California, United States|University of California San Francisco, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale Nephrology Clinical Research, New Haven, Connecticut, United States|Coastal Nephrology Associates Research Center, LLC, Port Charlotte, Florida, United States|Genesis Clinical Research, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|University of Maryland, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Rogosin Institute, New York, New York, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Baylor Scott & White Research Institute, Temple, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States","https://ClinicalTrials.gov/show/NCT03203642"
60,"Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)","Not yet recruiting","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Metformin XR|Other: Control","Western Sydney Local Health District, Sydney, New South Wales, Australia|Townsville University Hospital, Douglas, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia","https://ClinicalTrials.gov/show/NCT04939935"
61,"Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease","Completed","No Results Available","Polycystic Liver Disease|Polycystic Kidney, Autosomal Dominant","Drug: Ursodeoxycholic Acid","Radboud University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands|Academic Medical Centre Amsterdam, Amsterdam, Netherlands|Donostia University Hospital, San Sebastian, Spain","https://ClinicalTrials.gov/show/NCT02021110"
62,"Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","ADPKD","Other: water","Rigshospitalet, Copenhagen, Denmark","https://ClinicalTrials.gov/show/NCT02776241"
63,"Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Polycystic Kidney Disease, Autosomal Dominant","Drug: Tolvaptan|Drug: Placebo","Coastal Clinical Research, Mobile, Alabama, United States|University of South Alabama, Mobile, Alabama, United States|Apex Research of Riverside, Riverside, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|Coastal Nephrology Associates Research Center, LLC, Port Charlotte, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Renal Associates of Baton Rough, L.L.C., Baton Rouge, Louisiana, United States|John Hopkins School of Medicine, Baltimore, Maryland, United States|Tufts- New England Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mayo Medical Center, Rochester, Minnesota, United States|Erie County Medical Center, Buffalo, New York, United States|Nephrology Associates of Westchester, Hawthorne, New York, United States|The Rogosin Institute, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina, UNC, Kidney Center, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Kidney and Hypertension Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland/Case, Cleveland, Ohio, United States|Northwest Renal Clinic, Inc., Portland, Oregon, United States|University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States|Charleston Nephrology Associates, Charleston, South Carolina, United States|Nephrology Associates, P.C., Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Virginia, Nephrology Clinical Research Center, Charlottesville, Virginia, United States|Instituto de Nefrología, Nefrology SA, Buenos Aires, Argentina|Hospital Municipal de Vicente Lopez, Dr Bernardo Houssay, Buenos Aires, Argentina|Hosptial Universitario Austral, Buenos Aires, Argentina|Sanatorio Allende, Cordoba, Argentina|Hospital Privado-Centro Medico de Cordoba, Cordoba, Argentina|Royal Adelaide Hospital, Adelaide, Australia|Queen Elizebeth Hospital, Adelaide, Australia|Princess Alexandra Hospital, Brisbane, Australia|Royal Melbourne Hospital, Melbourne, Australia|Melbourne Renal Research Group, Melbourne, Australia|Royal Perth Hospital, Perth, Australia|Royal North Shore Hospital, Sydney, Australia|Westmead Hospital, Sydney, Australia|Ucl-St Luc, Brussels, Belgium|UZ Brussel, Brussel, Belgium|UZ Gent, Gent, Belgium|Queen Elizabeth II Health Science Center, Division of Nephrology, Halifax, Nova Scotia, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Hospital du Sacre- Coeur de Montreal, Montreal, Quebec, Canada|Herlev Amtssygehus, Herlev, Denmark|Odense Universitetshospital, Odense, Denmark|CHU-Hopital Pellegrin, Bordeaux, France|CHU - Hôpital Clémenceau, Caen Cedex, France|Hôpital Edouard Herriot, Lyon Cedex 3, France|Hôpital de la Conception, Marseille, France|CHU - Hôpital Lapeyronie, Montpellier, France|Hopital Bichat-Claude Bernard, Paris, France|Centre Hospitalier Universitaire, Reims cedex, France|CHU - Hôpital Nord, Saint-Etienne Cedex 2, France|Hopital Rangueil, Toulouse Cedex 09, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Nephrologische Gemeinschaftspraxis/Dialysezentrum, Düsseldorf, Germany|Klinik für Nieren- und Hochdruckkrankheiten, Essen, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätskliniken Heidelberg, Heidelberg, Germany|UH Erlangen/Nürnberg, Nuernberg, Germany|Ospedali Riuniti di Bergamo, Bergamo, Italy|Università Vita e Salute, Ospedale San Raffaele, Milano, Italy|Policlinico di Modena, Modena, Italy|Policlinico, Napoli, Italy|IRCCS Fondazione Salvatore Maugeri, Pavia, Italy|Fujita Health University Hospital, Toyoake, Aichi, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|Toranomon Hospital Kajigaya, Kawasaki, Kanagawa, Japan|Kitasato University Hospital, Sagamihara, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Osaka City University Hospital, Osaka-City, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Shuwa General Hospital, Kasukabe, Saitama, Japan|Saitama Medical Center, Kawagoe, Saitama, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, Japan|Jichi Medical School Hospital, Shimotsuke, Tochigi, Japan|Tokyo Medical & Dental University Hospital, Faculty of Medicine, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Teikyo University Hospital, Itabashi-ku, Tokyo, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|The Jikei University Hospital, Minato-Ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Chiba University Hospital, Chiba, Japan|National Hospital Organization Chiba-East Hospital, Chiba, Japan|Kyusyu University Hospital, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kumamoto Univeristy Hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|National Hospital Organization Kyoto Medical Center, Kyoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Ohno Memorial Hospital, Osaka, Japan|Saitama Medical Center Jichi Medical University, Saitama, Japan|VU Medisch Centrum, Amsterdam, Netherlands|UMCG Groningen, Groningen, Netherlands|Oddział Nefrologiczny Stacja Dializ, Ciechanow, Poland|Akademickie Centrum Kliniczne AMG, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1, Akademickie Centrum Kliniczne AMG, Gdansk, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Szpital Uniwersytecki w Krakowie, Krakow, Poland|SOP ZOZ Uniwersytecki Szpital Kliniczny, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie, Lublin, Poland|Klinika Chorób Wewnętrznych i Nefrologii, Warsaw, Poland|Międzyleski Szpital Specjalistyczny w Warszawie, Warsaw, Poland|Szpital Praski p.w. Przemienienia Panskiego, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Warszawa, Poland|Szpital Praski, Samodzielny Publiczny ZOZ, Warszawa, Poland|Akademicki Szpital Kliniczny im J Mikulicza Radeckiego, Wroclaw, Poland|Spitalul Clinic de Nefrologie Dr. Carol Davila, Bucharest, Romania|Institutul Clinic Fundeni, Bucharest, Romania|Spitalul Clinic ""C.I.Parhon"", Iasi, Romania|Kemerovo Medical Academy, Regional Clinical Hospital, Kemerovo, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|City Mariinskiy Hospital, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, St.-Petersburg, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, Russian Federation|Belfast City Hospital, Belfast, United Kingdom|Oueen Elizabeth Hospital, Birmingham, United Kingdom|Sussex Renal Unit Royal Sussex County Hospital, Brighton, United Kingdom|Uhcw Mhs Trust, Coventry, United Kingdom|Royal Infirmary, Edinburgh, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Royal Free and University College Medical School, London, United Kingdom|King's College Hospital, London, United Kingdom|St. George's Hospital, London, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|Morriston Hospital, Swansea, United Kingdom","https://ClinicalTrials.gov/show/NCT00428948"
64,"Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","ADPKD","Drug: Spironolactone|Drug: Sugar pill","UColorado, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT01853553"
65,"A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease","Completed","No Results Available","Polycystic Kidney Disease, Autosomal Dominant","Drug: RGLS4326","Balboa Nephrology Medical Group, La Mesa, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|Yale Nephrology Clinical Research, New Haven, Connecticut, United States|Accel Research Sites- Mid-Florida Kidney and Hypertension Care, Altamonte Springs, Florida, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|St. Clair Nephrology Research, Roseville, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|UT Southwestern Medical Center, Dallas, Texas, United States|ICON Early Phase Services, San Antonio, Texas, United States|Swedish Polycystic Kidney Disease Center, Seattle, Washington, United States","https://ClinicalTrials.gov/show/NCT04536688"
66,"Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease","Unknown status","No Results Available","Polycystic Kidney, Type 1 Autosomal Dominant Disease|Polycystic Kidney, Type 2 Autosomal Dominant Disease","Drug: Sirolimus|Drug: Placebo","Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria","https://ClinicalTrials.gov/show/NCT02055079"
67,"Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease","Completed","Has Results","Polycystic Kidney Disease","Drug: Pioglitazone|Drug: Placebo","Indiana University Health, Indianapolis, Indiana, United States","https://ClinicalTrials.gov/show/NCT02697617"
68,"Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control","Unknown status","No Results Available","Autosomal Dominant Polycystic Kidney Disease|Hypertension","Procedure: renal sympathetic denervation|Drug: antihypertensive drugs","Department of Nephrology, Shanghai Changzheng Hospital, Shanghai, Shanghai, China","https://ClinicalTrials.gov/show/NCT01932450"
69,"Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial","Completed","No Results Available","Polycystic Kidney, Type 1 Autosomal Dominant Disease","Procedure: Preimplantation Genetic Diagnosis","The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Navy General Hospital, Beijing, Beijing, China|Peking University Third Hospital, Beijing, Beijing, China|Southwest Hospital, Chongqing, Chongqing, China|Fuzhou General Hospital, Fuzhou, Fujian, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China|Hebei Province Center for Reproductive Medicine, Shijiazhuang, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Wuhan Tongji Hospital, Wuhan, Hubei, China|Wuhan Union Hospital, Wuhan, Hubei, China|Reproductive & Genetic Hospital of CITIC-Xiangya, Changsha, Hunan, China|Second Xiangya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital of Central South University, Changsha, Hunan, China|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China|The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|Shengjing Hospital, Shenyang, Liaoning, China|Hospital for Reproductive Medicine Affiliated to Shandong University, Jinan, Shandong, China|Shandong Provincial Hospital, Jinan, Shandong, China|Shanghai Changzheng Hospital, Shanghai, Shanghai, China|Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China|Tang-Du Hospital, Xi'an, Shanxi, China|Shanxi Provincial People's Hospital, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|West China Second University Hospital, Chengdu, Sichuan, China|Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang, China","https://ClinicalTrials.gov/show/NCT02948179"
70,"Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt","Recruiting","No Results Available","Polycystic Kidney, Autosomal Dominant|ADPKD|Autosomal Dominant Polycystic Kidney","Dietary Supplement: Sodiumchloride|Dietary Supplement: Protein|Dietary Supplement: Placebo comparator (salt)|Dietary Supplement: Placebo comparator (protein)","UMC Groningen, Groningen, Netherlands","https://ClinicalTrials.gov/show/NCT04310319"
71,"Tolvaptan-Octreotide LAR Combination in ADPKD","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Drug: Tolvaptan|Drug: Octreotide LAR|Other: Placebo","CRC per le Malattie Rare Aldo e Cele Daccò, Ranica, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT03541447"
72,"Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease","Terminated","No Results Available","Polycystic Kidney","Drug: tripterygium wilfordii|Drug: Emodin","Liu ZH, Yao XD,Chen X,Hu YL, Nanjing, Jiangsu, China|Yao Xiaodan, Nanjing, Jiangsu, China","https://ClinicalTrials.gov/show/NCT00801268"
73,"Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease","Active, not recruiting","No Results Available","Polycystic Kidney Disease, Adult|ADPKD","Drug: Lixivaptan","University of California Los Angeles, Los Angeles, California, United States|University of Chicago Medicine & Biological Sciences, Chicago, Illinois, United States|St. Clair Nephrology, Roseville, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Brookview Hills Research Associates, LLC, Winston-Salem, North Carolina, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|Nephrology Associates of Northern Virginia, Inc., Fairfax, Virginia, United States","https://ClinicalTrials.gov/show/NCT04152837"
74,"Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study","Completed","No Results Available","Kidney, Polycystic, Autosomal Dominant","Procedure: video thorascopic splanchnicectomy (VSPL)","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00571909"
75,"A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)","Completed","No Results Available","Autosomal Dominant Polycystic Kidney Disease","Other: ADPKD Diet","University of Kansas Medical Center, Kansas City, Kansas, United States","https://ClinicalTrials.gov/show/NCT01810614"
76,"Study of Lanreotide to Treat Polycystic Kidney Disease","Unknown status","No Results Available","Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Drug: Lanreotide","University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands","https://ClinicalTrials.gov/show/NCT01616927"
77,"Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","Has Results","Polycystic Kidney Diseases","Drug: Rapamune","The Cleveland Clinic- main campus, Cleveland, Ohio, United States","https://ClinicalTrials.gov/show/NCT00286156"
78,"Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","Completed","No Results Available","ADPKD","Other: Ketogenic diet|Other: 3-days water-fasting|Other: Control","Department II of Internal Medicine, University Hospital of Cologne, Cologne, Germany","https://ClinicalTrials.gov/show/NCT04680780"
79,"Renal Denervation in ADPKD- RDN-ADPKD Study","Recruiting","No Results Available","Uncontrolled Hypertension|Autosomal Dominant Polycystic Kidney Disease|Renal Denervation","Device: Renal denervation","University Hospital FAU Erlangen-Nürnberg, Erlangen, Germany","https://ClinicalTrials.gov/show/NCT05460169"
80,"Statin Therapy in Patients With Early Stage ADPKD","Recruiting","No Results Available","ADPKD|Autosomal Dominant Polycystic Kidney","Drug: Pravastatin|Drug: Placebo","University of Colorado Denver Anschutz Medical Campus, Denver, Colorado, United States","https://ClinicalTrials.gov/show/NCT03273413"
81,"Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease","Unknown status","No Results Available","ADPKD","Drug: Metformin|Drug: Tolvaptan","AOUC ""Policlinico"", Bari, Italy|AOUConsorziale Policlinico Di Bari, Bari, Italy","https://ClinicalTrials.gov/show/NCT03764605"
82,"Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)","Unknown status","No Results Available","Kidney, Polycystic, Autosomal Dominant","Drug: Cilnidipine|Drug: Imidapril","Department of Medicine II, Hokkaido Univserity School of Medicine, Sapporo, Hokkaido, Japan|Toranomon Hospital Kajigaya, Kidney center, Kawasaki, Kanagawa, Japan|Department of Medicine II, Nippon Medical School, Bunkyo-ku, Tokyo, Japan|Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan|Toranomon Hospital, Kidney center, Minato-ku, Tokyo, Japan|Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan|Department of Urology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan|Department of Urology, National Hospital Organaization Chiba-East Hospital, Chiba, Japan|Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan","https://ClinicalTrials.gov/show/NCT00890279"
83,"Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat","Terminated","No Results Available","Congenital Cystic Kidney Disease","Drug: Venglustat GZ402671","Investigational Site Number :8400019, Morgantown, West Virginia, United States|Investigational Site Number :0360001, Westmead, New South Wales, Australia|Investigational Site Number :0560002, Leuven, Belgium|Investigational Site Number :2500002, Paris, France|Investigational Site Number :2760001, Berlin, Germany|Investigational Site Number :3920001, Sapporo-shi, Hokkaido, Japan|Investigational Site Number :3920007, Osaka-shi, Osaka, Japan|Investigational Site Number :3920002, Bunkyo-ku, Tokyo, Japan|Investigational Site Number :3920004, Shinjuku-ku, Tokyo, Japan|Investigational Site Number :4100002, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Investigational Site Number :5280002, Nijmegen, Netherlands|Investigational Site Number :6420002, Bucuresti, Romania|Investigational Site Number :7240003, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240002, Madrid / Madrid, Madrid, Comunidad De, Spain","https://ClinicalTrials.gov/show/NCT04705051"
84,"Daily Caloric Restriction in ADPKD","Recruiting","No Results Available","Autosomal Dominant Polycystic Kidney|Overweight and Obesity","Behavioral: Daily caloric restriction|Other: Standard advice control","University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States","https://ClinicalTrials.gov/show/NCT04907799"
85,"Dietary Intervention in ADPKD on Tolvaptan","Unknown status","No Results Available","Polyuria|Autosomal Dominant Polycystic Kidney","Other: Dietary","St. Joseph's Healthcare, Hamilton, Ontario, Canada","https://ClinicalTrials.gov/show/NCT03858439"
86,"A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease","Recruiting","No Results Available","Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney","Drug: Leuprorelin","Radboudumc, Nijmegen, Gelderland, Netherlands|Groningen universitair medical center, Groningen, Netherlands","https://ClinicalTrials.gov/show/NCT05478083"
87,"Lanreotide as Treatment of Polycystic Livers","Completed","No Results Available","Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Polycystic Kidney, Autosomal Dominant","Drug: Placebo|Drug: Lanreotide","University Hospital Gasthuisberg, Leuven, Belgium|Radboud University Medical Center, Nijmegen, Netherlands","https://ClinicalTrials.gov/show/NCT00565097"
88,"PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration","Not yet recruiting","No Results Available","Autosomal Dominant Polycystic Kidney Disease|Nephrogenic Diabetes Insipidus|Acquired Nephrogenic Diabetes Insipidus|Congenital Nephrogenic Diabetes Insipidus","Drug: PB","Mayo Clinic, Jacksonville, Florida, United States","https://ClinicalTrials.gov/show/NCT05190744"
89,"Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303","Terminated","No Results Available","Polycystic Kidney Disease, Adult","Drug: Lixivaptan","Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States","https://ClinicalTrials.gov/show/NCT05208866"
90,"An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)","Recruiting","No Results Available","Chronic Kidney Diseases|Alport Syndrome|Autosomal Dominant Polycystic Kidney","Drug: Bardoxolone methyl","University of Alabama at Birmingham, Birmingham, Alabama, United States|Nephrology Consultants, LLC, Huntsville, Alabama, United States|Arizona Kidney Disease and Hypertension Research Services, PLLC, Glendale, Arizona, United States|California Institute Renal Research, La Mesa, California, United States|Academic Medical Research Institute, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Apex Research of Riverside, Riverside, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco - Children's Renal Center, San Francisco, California, United States|Western Nephrology, Arvada, Colorado, United States|Colorado Kidney Care, PC, Denver, Colorado, United States|South Florida Research Institute, Lauderdale Lakes, Florida, United States|USF Health South Tampa Center, Tampa, Florida, United States|Florida Premier Research Institute, LLC, Winter Park, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Boise Kidney & Hypertension, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension, PLLC, Meridian, Idaho, United States|Northwestern University, Chicago, Illinois, United States|Nephrology Research NorthShore University Health System, Evanston, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Renal Associates of Baton Rouge, Baton Rouge, Louisiana, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|The Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center - Division of Nephrology, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Nephrology Center, PC, Kalamazoo, Michigan, United States|Children's Mercy Hospital and Clinics, Kansas City, Missouri, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Nephrology Associates, PC, Flushing, New York, United States|Columbia University Medical Center, New York, New York, United States|Mountain Kidney & Hypertension Associates, Asheville, North Carolina, United States|Metrolina Nephrology Associates, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Metrolina Nephrology Associates, Gastonia, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Columbia Nephrology Associates, PA, Columbia, South Carolina, United States|South Carolina Nephrology & Hypertension Center, Inc, Orangeburg, South Carolina, United States|Research Management, Inc., Austin, Texas, United States|Renal Disease Research Institute, Dallas, Texas, United States|DaVita Med Center, Houston, Texas, United States|Southwest Houston Research, Houston, Texas, United States|Clinical Advancement Center, San Antonio, Texas, United States|John Hunter Hospital, New Lambton, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Melbourne Renal Research Group, Reservoir, Victoria, Australia|Chu Grenoble Alpes, Grenoble, France|Hopital Necker, Universite Paris Descartes, Paris, France|Japanese Red Cross Nagoya Daini Hospital, Nagoya-shi, Aichi, Japan|Kobe University Hospital, Kobe City, Hyogo, Japan|St Marianna University Hospital, Kawasaki, Kanagawa, Japan|JCHO Sendai Hospital, Sendai-shi, Miyagi, Japan|Kitano Hospital, Osaka-shi, Osaka, Japan|Saga University Hospital, Saga-shi, Saga, Japan|Saitama Children's Medical Center, Saitama-shi, Saitama, Japan|Jutendo University Hospital, Bunkyō-Ku, Tokyo, Japan|Tokyo Metropolitan Children's Medical Center, Fuchū, Tokyo, Japan|Puerto Rico Clinical and Translational Research Consortium (PRCTRC), Rio Piedras, Puerto Rico|Fundacio Puigvert, Barcelona, Cataluna, Spain|Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain","https://ClinicalTrials.gov/show/NCT03749447"
91,"CCB Safety Study in Treatment of Hypertension of ADPKD","Unknown status","No Results Available","Kidney, Polycystic, Autosomal Dominant","Drug: Candesartan|Drug: Candesartan and Cilnidipine|Drug: Candesartan plus non-CCB agents","Kyorin University School of Medicine, Mitaka, Tokyo, Japan|Department of Urology, National Hospital Organaization Chiba-East Hospital, Chiba, Chiba, Japan|Toranomon Hospital Kajigaya, Kidney center, Kanagawa, Japan|Toranomon Hospital, Kidney center, Tokyo, Japan|Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan|Department of Urology, Teikyo University, School of Medicine, Tokyo, Japan","https://ClinicalTrials.gov/show/NCT00541853"
92,"Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function","Unknown status","No Results Available","Adult Polycystic Kidney Disease|Kidney Neoplasms|Kidney Dysfunction","Diagnostic Test: sinistrin clearance dynamic measurement","University Hospital Zurich, Zürich, Switzerland","https://ClinicalTrials.gov/show/NCT03442647"
93,"High Water Intake to Slow Progression of Polycystic Kidney Disease","Completed","Has Results","Kidney, Polycystic, Autosomal Dominant","Other: Water","New York University Langone Medical Center, New York, New York, United States","https://ClinicalTrials.gov/show/NCT00784030"
94,"Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts","Not yet recruiting","No Results Available","Liver Cyst|Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney|Autosomal Dominant Polycystic Liver Disease","Procedure: aspiration sclerotherapy versus laparoscopic fenestration",,"https://ClinicalTrials.gov/show/NCT05500157"
95,"Pasireotide LAR in Severe Polycystic Liver Disease","Completed","Has Results","Somatostatin Analogs|Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney Disease|Autosomal Dominant Polycystic Liver Disease","Drug: Pasireotide LAR|Drug: Placebo","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT01670110"
96,"Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety","Completed","No Results Available","Polycystic Kidney","Drug: Sirolimus|Drug: conventional therapy","Hospital ""Azienda Ospedaliera Ospedali Riuniti di Bergamo"" Unit of Neprology and Dialysis, Bergamo, Italy","https://ClinicalTrials.gov/show/NCT00491517"
97,"A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX","Completed","Has Results","IgA Nephropathy|CKD Associated With Type 1 Diabetes|Focal Segmental Glomerulosclerosis|Autosomal Dominant Polycystic Kidney","Drug: Bardoxolone methyl capsules","University of Alabama Birmingham, Birmingham, Alabama, United States|Phoenician Centers for Research & Innovation (PCRI), Phoenix, Arizona, United States|University of California Los Angeles, Los Angeles, California, United States|Denver Nephrology, Denver, Colorado, United States|Gulfcoast Endocrine and Diabetes Center, Clearwater, Florida, United States|South Florida Research Institute, Lauderdale Lakes, Florida, United States|Coastal Nephrology Associates, Port Charlotte, Florida, United States|Kidney Care Augusta, Augusta, Georgia, United States|Boise Kidney & Hypertension, PLLC, Caldwell, Idaho, United States|Boise Kidney & Hypertension, PLLC, Meridian, Idaho, United States|Research By Design, Evergreen Park, Illinois, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Four Rivers Clinical Research, Inc, Paducah, Kentucky, United States|Northwest Louisiana Nephrology, Shreveport, Louisiana, United States|Tufts Medical Center - Division of Nephrology Tufts Medical Center, Boston, Massachusetts, United States|Clinical Research Consultants, LLC, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Jacobi Medical Center, Bronx, New York, United States|Columbia University Medical Center - Nephrology, New York, New York, United States|Physician's East Endocrine Research, Greenville, North Carolina, United States|Remington-Davis Clinical Research, Columbus, Ohio, United States|Northeast Clinical Research Center, LLC, Bethlehem, Pennsylvania, United States|The Warren Alpert School of Brown University, Providence, Rhode Island, United States|Nephrology Associates, Chattanooga, Tennessee, United States|Research Management, Inc., Austin, Texas, United States|Renal Disease Research Intitute, Dallas, Texas, United States|Renal Associates, PA, San Antonio, Texas, United States|Advanced Clinical Research, West Jordan, Utah, United States|Mendez Center for Clinical Research LLC, Fairfax Station, Virginia, United States|Larry Stonesifer, M.D., Federal Way, Washington, United States","https://ClinicalTrials.gov/show/NCT03366337"
98,"Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease","Completed","No Results Available","Chronic Renal Failure|Polycystic Kidney Disease","Biological: Intravenous injection autologous mesenchymal stem cells","Royan Institute, Tehran, Iran, Islamic Republic of","https://ClinicalTrials.gov/show/NCT02166489"
99,"Octreotide in Severe Polycystic Liver Disease","Completed","Has Results","Polycystic Kidney, Autosomal Dominant|Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Kidney, Polycystic|Abdominal Pain","Drug: Octreotide|Drug: Placebo","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00426153"
100,"A Study of RGLS8429 in Healthy Volunteers","Recruiting","No Results Available","Healthy Volunteers","Drug: RGLS8429|Drug: Placebo volume-matching RGLS8429 dose","ICON Early Phase Services, San Antonio, Texas, United States","https://ClinicalTrials.gov/show/NCT05429073"
101,"Polycystic Liver Disease in Kidney Transplant","Terminated","Has Results","Polycystic Liver Disease","Drug: Tacrolimus|Drug: Sirolimus|Drug: Mycophenolate Mofetil|Drug: Prednisone","Mayo Clinic, Rochester, Minnesota, United States","https://ClinicalTrials.gov/show/NCT00934791"
102,"The Vienna RAP Pilot Study","Completed","No Results Available","ADPKD","Drug: Sirolimus","Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria","https://ClinicalTrials.gov/show/NCT01632605"
103,"Open-Label Extension of LOCKCYST Trial","Unknown status","No Results Available","Polycystic Liver Disease|Hepatomegaly|Liver Diseases|Polycystic Kidney|Autosomal Dominant","Drug: lanreotide","University Hospital Gasthuisberg, University of Leuven, Leuven, Belgium|Radboud University Nijmegen Medical Center, Nijmegen, Netherlands","https://ClinicalTrials.gov/show/NCT00771888"
